Eye Insights Issue 2: Fueling a Revolution in Retinal Care

How biomedical breakthroughs in anti-VEGF research have changed how we diagnose, treat, and save vision for patients with retinal disease.

Eye Insights
Download PDF (2.37 MB)


  • Annually, 500,000 ophthalmic patients in the United States and over 1 million worldwide are treated with all anti-VEGF agents combined.
  • Anti-VEGF treatments have been shown to halt vision loss in more than 90 percent of patients with AMD and to improve vision in one-third.
  • VEGF inhibitors hold potential for a growing list of indications, including neovascular glaucoma and retinopathy of prematurity.
  • VEGF inhibitors have been used experimentally to treat over 50 ocular diseases.


Editor-in-Chief: Joan W. Miller, MD, FARVO
Managing Editor: Matthew F. Gardiner, MD
Communications Director: Suzanne Ward
Scientific Communications Manager: Wendy Chao, PhD
Clinical Advisory Group: Carolyn E. Kloek, MD, Deeba Husain, MD, Ankoor S. Shah, MD, PhD, Angela V. Turalba, MD

Browse all issues >>    |    Email: eyeinsights@meei.harvard.edu


eyeinsights-jan-2015.pdf2.37 MB
See also: Eye Insights